Powerful new tool promises major advances in cancer treatment
Grant and Award Announcement
Updates every hour. Last Updated: 29-Apr-2025 04:08 ET (29-Apr-2025 08:08 GMT/UTC)
New Australian technology is set to transform the way that gastrointestinal cancers are detected and treated with precise, minimally invasive surgery.
As many as one in 3,000 people could be carrying a faulty gene that significantly increases their risk of a punctured lung, according to new estimates from Cambridge researchers. Previous estimates had put this risk closer to one in 200,000 people. The gene in question, FLCN, is linked to a condition known as Birt-Hogg-Dubé syndrome, symptoms of which include benign skin tumours, lung cysts, and an increased risk of kidney cancer.
Even in the case of uncomplicated infections, the body prepares itself early on for the possibility of a more severe course. A research team from the Technical University of Munich (TUM) and Helmholtz Munich has now uncovered this mechanism. The scientists showed that, right at the onset of mild illness, the body also produces special T cells previously known only from chronic, severe infections and tumors.
Lysosomes are considered as the major degradative site and were recently recognized as dynamic regulators of cellular homeostasis. Many diseases, including cancer, have been linked to functional changes in lysosomes. Natural products and their structural analogs have historically made major contributions to pharmacotherapy. By employing the natural small molecule isowalsuranolide as a chemical probe, the underlying mechanisms of its lysosome-inducing effects were investigated. This study revealed that isowalsuranolide targets TrxR1/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB/TFE3 axis. This study provides important insight into the lysosomal adaptation mechanism to redox signals and the application of lysosome-inducing agents in the treatment of lysosome-related diseases, including cancer.